Pancreatic Exosomes

Overview

Parent Cell: Akira Pancreatic Beta Cells differentiated from UCT-WJ-MSCs | Pancreatic growth factors and miRNAs for pancreatic beta cell repair and regeneration

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

The Akira Pancreatic Exosome Matrix is harvested from pancreatic beta-like cells produced through a multi-stage differentiation protocol mimicking pancreatic endocrine development: definitive endoderm induction (Activin-A/Wnt3a), pancreatic progenitor specification (FGF10/Noggin/EGF), and terminal beta cell maturation (Betacellulin/IGF-1/nicotinamide). The resulting cells express PDX1, Nkx6.1, and insulin with glucose-stimulated insulin secretion (GSIS) capacity.

Pancreatic beta cell-derived exosomes carry a highly specialized cargo: miR-375 is the defining beta cell miRNA, regulating glucose homeostasis and insulin secretion. miR-7 suppresses the mTOR pathway in beta cells while also inhibiting NLRP3 in immune cells, providing both beta cell-intrinsic regulation and immune protection of residual islet mass. The secretome delivers EGF, HGF, and Betacellulin — all established beta cell survival and regeneration factors.

Mechanism of Action

Beta Cell Survival & Protection: IGF-1 and EGF cargo activate PI3K/Akt survival signaling in beta cells, protecting against cytokine-induced apoptosis (IL-1β, TNF-α, IFN-γ) — the primary mechanism of beta cell destruction in Type 1 diabetes. HGF via Met receptor provides additional anti-apoptotic protection and promotes beta cell proliferation.^[1]

Immune Tolerance Induction: miR-146a suppresses NF-κB in pancreatic-infiltrating macrophages and T cells, reducing islet inflammation. IL-10 and TGF-β1 from the secretome promote regulatory T cell (Treg) expansion around residual islet mass. miR-7 inhibits NLRP3 inflammasome activation, blocking IL-1β — a key cytokine in both T1DM and T2DM islet destruction.

Beta Cell Regeneration & Neogenesis: Betacellulin and EGF drive proliferation of ductal progenitor cells and transdifferentiation toward beta-like cells. HGF promotes endocrine progenitor expansion. miR-375 cargo delivers beta cell identity signals that promote maintenance of the beta cell gene expression program in residual and regenerating islet cells.^[2]

Insulin Sensitivity & Glucose Metabolism: GLP-1-associated secretome factors and IGF-1 improve peripheral insulin sensitivity and hepatic glucose uptake independently of beta cell function. This dual mechanism — islet protection combined with peripheral insulin sensitization — addresses both the secretory defect and the insulin resistance components of Type 2 diabetes.

Key Molecular Cargo

Therapeutic Applications

???

Clinical & Preclinical Evidence

???